Imaging Biometrics (IBAI) Stock Overview
Through its subsidiaries, provides clinical treatments to patients in the field of medical imaging diagnostics in the United Kingdom, Switzerland, European Union, and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
IBAI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Imaging Biometrics Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.011 |
| 52 Week High | UK£0.021 |
| 52 Week Low | UK£0.0052 |
| Beta | 2.59 |
| 1 Month Change | 82.54% |
| 3 Month Change | 60.84% |
| 1 Year Change | -4.17% |
| 3 Year Change | -34.29% |
| 5 Year Change | -76.29% |
| Change since IPO | -68.28% |
Recent News & Updates
Shareholder Returns
| IBAI | GB Healthcare Services | GB Market | |
|---|---|---|---|
| 7D | 91.7% | 1.7% | 2.2% |
| 1Y | -4.2% | 21.2% | 13.4% |
Return vs Industry: IBAI underperformed the UK Healthcare Services industry which returned 21.2% over the past year.
Return vs Market: IBAI underperformed the UK Market which returned 13.4% over the past year.
Price Volatility
| IBAI volatility | |
|---|---|
| IBAI Average Weekly Movement | 26.6% |
| Healthcare Services Industry Average Movement | 5.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.8% |
| 10% least volatile stocks in GB Market | 2.4% |
Stable Share Price: IBAI's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: IBAI's weekly volatility has increased from 16% to 27% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1965 | 7 | Trevor Brown | www.iqai.ltd |
Imaging Biometrics Ltd., through its subsidiaries, provides clinical treatments to patients in the field of medical imaging diagnostics in the United Kingdom, Switzerland, European Union, and the United States. It operates through Holding Company, Medical Software, and Oral Gallium Maltolate (GaM) segments. The company develops ready-to-use software applications for the healthcare industry comprising IB Clinic for all IB software platforms; IB Neuro, a MR DSC perfusion processing platform; IB Delta Suite, which creates Delta T1 maps from routine MR exams; IB DCE and IB Diffusion that provide whole body insights on blood flow and water diffusion; StoneChecker and Liver Surface Nodularity, which are computed tomography processing applications designed to assist clinicians in the non-invasive assessment of kidney stones and liver health; IB ASL to measure cerebral blood flow to assess stroke, dementia, and other neurological conditions; IB Zero G, a technology designed to eliminate the need for gadolinium contrast agents in standard imaging; and IB Nimble, which supports healthcare providers through virtual collaboration among clinicians.
Imaging Biometrics Ltd. Fundamentals Summary
| IBAI fundamental statistics | |
|---|---|
| Market cap | UK£2.84m |
| Earnings (TTM) | -UK£142.45k |
| Revenue (TTM) | UK£699.86k |
Is IBAI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IBAI income statement (TTM) | |
|---|---|
| Revenue | UK£699.86k |
| Cost of Revenue | UK£9.76k |
| Gross Profit | UK£690.10k |
| Other Expenses | UK£832.54k |
| Earnings | -UK£142.45k |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.00058 |
| Gross Margin | 98.61% |
| Net Profit Margin | -20.35% |
| Debt/Equity Ratio | 0% |
How did IBAI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/05 03:51 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Imaging Biometrics Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew McEachran | Singer Capital Markets |